|
| Subject | Treatment | Dose, frequency, time | Effects | Reference |
|
| Anovulatory Chinese women with polycystic ovary syndrome | BBR, (69 normal weight and 29 overweight/obese) | 1.2 g/d, thrice daily, 4 months | T-C (−17%), LDL-C (−12%), and TAG (−37%) | [36] |
|
| Hyperlipidemic subjects | BBR-containing , (15/15, M/F); Placebo, (3/6, M/F) | 0.2 g/d, once daily, 12 wk | Non-HDL-C (−15%), LDL-C (−19%) | [37] |
|
| Moderately hypercholesterolemic subjects | AP-1, (18/33, M/F);
Placebo, (14/37, M/F) | 500 mg/d, once a day, 12 wk | TC (−5%), LDL-C (−7.8%) | [38] |
|
| Patients with type-2 diabetes | BBR, (17/20, M/F); compared to baseline | 0.9 g/d, thrice daily, 3 months | T-C (−11%), LDL-C (−16%), TAG (−21%) | [39] |
|
| Hypercholesterolemic patients | BBR, (35/28, M/F); Placebo, (17/11, M/F) | 1 g/d, twice daily, 3 months | T-C (−29%), LDL-C (−25%), TAG (−35%) | [7] |
|
| Hypercholesterolemic patients | BBR, ; compared to baseline (no sex ratio provided) | 1 g/d, twice daily, 2 months | TC (−21.8%), LDL-C (−23.8%), TAG (−22.1%) | [40] |
|
| Patients with type-2 diabetes | BBR, ; compared to baseline (no sex ratio provided) | 1.5 g/d, thrice daily, 13 wk | TC (−13%), TAG (−21%) | [41] |
|
| Patients with type-2 diabetes | BBR, (27/23, M/F); compared to baseline | 1 g/d, twice daily, 2 months | TAG (−18%). | [42] |
|
| Patients with type-2 diabetes and dyslipidemia | BBR, (30/28, M/F); Placebo, (31/21, M/F) | 1 g/d, twice daily, 3 months | T-C (−18%), LDL-C (−21%), TAG (−36%) | [43] |
|
| Caucasians with low cardiovascular risk | BBR, (35/36, M/F); Placebo, (35/35, M/F) | 1 g/d, twice daily, 3 months | T-C (−11.6%), LDL-C (−16.4%), TAG (−21.2%), HDL-C (+9.1%) | [44] |
|
| Dyslipidemic patients | AP-, (416/518, M/F); Placebo, (384/434, M/F) | 500 mg/d, once daily, 16 wk | T-C (−10%), LDL-C (−13%), TAG (−7%), HDL-C (+8%) | [45] |
|
| Patients with metabolic syndrome | BBR, ; Placebo, (no sex ratio provided) | 1.5 g/d, thrice daily, for 3 months | TAG (−42%) | [46] |
|
| Patients on hormone-therapy after breast cancer | AP-1, ; compared to baseline | 500 mg/d, once daily, 3 months | T-C (−15%), LDL-C (−19%), TAG (−37%) | [47] |
|
| Hypercholesterolemic subjects | AP-1, (62/90, M/F); compared to baseline | 500 mg/d, once daily, 6 months | TC (−24%), LDL-C (−32%), non-HDL-C (−30%), TAG (−20%) | [48] |
|
| Moderate dyslipidemic subjects | BBR, (8/12, M/F); AP-1, (8/12, M/F) | 500 mg/d, once daily, 4 wk | T-C (−16%), LDL-C (−20%), TAG (−22%), HDL-C (+7%); AP-1 and BBR did not differ | [49] |
|
| Patients with type-2 diabetes | , (17/5, M/F); compared to baseline | 500 mg/d, once daily, 90 d | T-C (−21%), LDL-C (−19%), TAG (−44%) | [50] |
|
| Obese Caucasians | BBR, , compared to baseline (no sex ratio provided) | 1.5 g/d, thrice daily, 12 wk | T-C (−12%), TAG (−23%) | [25] |
|
| Patients with metabolic syndrome | AP-1, (20/9, M/F); Placebo, (18/12, M/F) | 500 mg/d, once daily, 18 wk | T-C (−15%), LDL-C (−23%) | [51] |
|
| Menopausal women with moderate dyslipidemia | BBR + Isoflavones, ; compared to baseline | Isoflavones and BBR combination, 12 wk | T-C (−14%), LDL-C (−12%), TAG (−19%) | [52] |
|
| Elderly (>75 yr) hypercholesterolemic patients | AP-1, (21/19, M/F); Placebo, (20/20, M/F) | 500 mg/d, once daily, 12 months | T-C (−20%), LDL-C (−31%) | [53] |
|
| Patients with polycystic ovary syndrome and insulin resistance | BBR. ; compared to baseline | 1.5 g/d, thrice daily, 3 months | T-C (−17%), LDL-C (−14%), TAG (−17%), HDL-C (+12%) | [54] |
|
| Hypercholesterolemic patients | AP-1, (13/12, M/F); Placebo, (13/12, M/F) | 500 mg/d, once daily, 6 wk | T-C (−17%), LDL-C (−23%) | [55] |
|
